GEN Exclusives

More »

GEN News Highlights

More »
Mar 5, 2007

Lilly to Acquire Sleep Disorder-Focused Company

  • Eli Lilly and Company will acquire Hypnion, a privately held neuroscience drug discovery company focused on sleep disorders. “The acquisition of Hypnion provides Lilly with a broader and more substantive presence in the area of sleep disorder research,” remarks Steven M. Paul, M.D., executive vp, science and technology for Lilly.

    “Hypnion has leveraged its expertise in this area to develop both innovative technologies and molecules, including the promising insomnia compound HY10275.”

    HY10275 is a dual-acting H1/5HT2a compound that uses Hypnion’s SCORE-2004™ technology. Earlier in 2007, Hypnion reported that the candidate met the primary and secondary endpoints in the initial Phase II trial at doses of 1 mg and 3 mg in adults with transient insomnia.

    The companies expect the transaction to close near the end of the first quarter of 2007.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »